About: Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus
Creator	Choi, Hyeree Muthumani, Kar Reed, Charles Tebas, Pablo Esquivel, Rianne Jeong, Moonsup White, Scott Kobinger, Gary Maslow, Joel Kim, J Kudchodkar, Sagar Reuschel, Emma Weiner, David Kwon, Jin-Ah
topic	covid:045e3571c820280e2d7b89537c1cd78ece60ab7b#this
source	Elsevier; Medline; PMC
abstract	Vaccines are considered one of the greatest advances in modern medicine. The global burden of numerous infectious diseases has been significantly reduced, and in some cases, effectively eradicated through the deployment of specific vaccines. However, efforts to develop effective vaccines against infectious pathogens such as influenza, HIV, dengue virus (DENV), chikungunya virus (CHIKV), Ebola virus, and Zika virus (ZIKV) have proven challenging. Zika virus is a mosquito-vectored flavivirus responsible for periodic outbreaks of disease in Africa, Southeast Asia, and the Pacific Islands dating back over 50 years. Over this period, ZIKV infections were subclinical in most infected individuals and resulted in mild cases of fever, arthralgia, and rash in others. Concerns about ZIKV changed over the past two years, however, as outbreaks in Brazil, Central American countries, and Caribbean islands revealed novel aspects of infection including vertical and sexual transmission modes. Cases have been reported showing dramatic neurological pathologies including microcephaly and other neurodevelopmental problems in babies born to ZIKV infected mothers, as well as an increased risk of Guillain-Barre syndrome in adults. These findings prompted the World Health Organization to declare ZIKV a public health emergency in 2016, which resulted in expanded efforts to develop ZIKV vaccines and immunotherapeutics. Several ZIKV vaccine candidates that are immunogenic and effective at blocking ZIKV infection in animal models have since been developed, with some of these now being evaluated in the clinic. Additional therapeutics under investigation include anti-ZIKV monoclonal antibodies (mAbs) that have been shown to neutralize infection in vitro as well as protect against morbidity in mouse models of ZIKV infection. In this review, we summarize the current understanding of ZIKV biology and pathogenesis and describe our efforts to rapidly develop a vaccine against ZIKV.
has issue date	2018-12-01(xsd:dateTime)
bibo:doi	10.1016/j.micinf.2018.03.001
bibo:pmid	29555345
has license	hybrid-oa
sha1sum (hex)	045e3571c820280e2d7b89537c1cd78ece60ab7b
schema:url	https://doi.org/10.1016/j.micinf.2018.03.001
resource representing a document's title	Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus
has PubMed Central identifier	PMC6593156
has PubMed identifier	29555345
schema:publication	Microbes and Infection
resource representing a document's body	covid:045e3571c820280e2d7b89537c1cd78ece60ab7b#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/045e3571c820280e2d7b89537c1cd78ece60ab7b
is schema:about of	named entity 'These' named entity 'develop' named entity 'individuals' named entity 'develop' named entity 'evaluated' named entity 'specific' named entity 'arthralgia' named entity 'CHIKV' named entity 'Ebola virus' named entity 'vaccine' named entity '2016' named entity 'period' named entity 'microcephaly' named entity 'Africa' named entity 'problems' named entity 'expanded' named entity 'neurodevelopmental' named entity 'developed' named entity 'outbreaks' named entity 'global' named entity 'Zika virus' named entity 'dramatic' named entity 'Rapid' named entity 'arthralgia' named entity 'infection' named entity 'sexual transmission' named entity 'public health emergency' named entity 'HIV' named entity 'Zika' named entity 'infection' named entity 'ZIKV' named entity 'ZIKV' named entity 'mouse models' named entity 'Zika virus' named entity 'modern medicine' named entity 'morbidity' named entity 'virus' named entity 'infection' named entity 'Vaccines' named entity 'cellular membranes' named entity 'preclinical' named entity 'correlation' named entity 'immunizations' named entity 'JEV' named entity 'mosquitos' named entity 'antigen' named entity 'DENV' named entity 'infection' named entity 'correlation' named entity 'Passive transfer' named entity 'mice' named entity 'vaccine' named entity 'vaccine design' named entity 'vaccine' named entity 'embryo' named entity 'Aedes' named entity 'Africa' named entity 'urine' named entity 'WHO' named entity 'United States' named entity 'Studies examining' named entity 'clinical evidence' named entity 'ZIKV' named entity 'ZIKV' named entity 'wild type' named entity 'ZIKV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software